Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma.

Megestrol acetate plus low-dose estrogen may be an effective, low-cost alternative to pharmacologic or surgical castration plus flutamide in the management of patients with advanced prostate cancer. The potential benefit of combined androgen ablation achieved by any means in comparison with conventional hormonal therapy appears to be limited.